Iovance Biotherapeutics (IOVA)
(Delayed Data from NSDQ)
$10.97 USD
-2.49 (-18.48%)
Updated May 10, 2024 04:00 PM ET
After-Market: $10.96 -0.01 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Iovance Biotherapeutics (IOVA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$25.83 | $34.00 | $19.00 | 92.04% |
Price Target
Based on short-term price targets offered by 12 analysts, the average price target for Iovance Biotherapeutics comes to $25.83. The forecasts range from a low of $19.00 to a high of $34.00. The average price target represents an increase of 92.04% from the last closing price of $13.45.
Analyst Price Targets (12)
Broker Rating
Iovance Biotherapeutics currently has an average brokerage recommendation (ABR) of 1.14 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 14 brokerage firms. The current ABR compares to an ABR of 1.14 a month ago based on 14 recommendations.
Of the 14 recommendations deriving the current ABR, 13 are Strong Buy, representing 92.86% of all recommendations. A month ago, Strong Buy represented 92.86%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 13 | 13 | 13 | 13 | 13 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.14 | 1.14 | 1.14 | 1.14 | 1.14 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/14/2024 | Piper Sandler | Joseph M Catanzaro | Strong Buy | Strong Buy |
3/7/2024 | Truist Securities | Asthika S Goonewardene | Strong Buy | Strong Buy |
2/29/2024 | H.C. Wainwright & Co. | Joseph Pantginis | Strong Buy | Strong Buy |
2/20/2024 | Chardan Capital Markets | Yevgeniya Livshits | Strong Buy | Strong Buy |
2/20/2024 | JMP Securities | Reni Benjamin | Strong Buy | Strong Buy |
2/19/2024 | Robert W. Baird & Co. | Colleen M Kusy | Strong Buy | Strong Buy |
10/2/2023 | Guggenheim Securities | Kelsey Goodwin | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.14 |
ABR (Last week) | 1.14 |
# of Recs in ABR | 14 |
Average Target Price | $25.83 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 84 of 252 |
Current Quarter EPS Est: | -0.39 |